Previous 10 | Next 10 |
Eiger BioPharmaceuticals (NASDAQ:EIGR) announces that the U.S. FDA has granted Breakthrough Therapy Designation for avexitide for the treatment of congenital hyperinsulism (HI). Shares up more than 11% premarket. Breakthrough Therapy status is a process designed to expedite the deve...
Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism - All Five Orphan Programs Now Have Breakthrough Therapy Designation PR Newswire PALO ALTO, Calif. , Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceu...
Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences PR Newswire PALO ALTO, Calif. , Aug. 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development...
Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5 - Live Conference Call and Webcast at 4:30 PM ET - PR Newswire PALO ALTO, Calif. , July 22, 2021 /PRNewswire/ -- Eiger BioPhar...
Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference PR Newswire PALO ALTO, Calif. , July 7, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on t...
Eiger BioPharmaceuticals (EIGR) announces that the first patients were dosed with Peginterferon Lambda (Lambda) in the Phase 3 TOGETHER platform study in outpatients with COVID-19.TOGETHER is a multi-center, investigator-sponsored, randomized, placebo-controlled Phase 3 study evaluating ...
Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients - Lambda is administered as a one-time, outpatient, subcutaneous dose PR Newswire PALO ALTO, Calif. , Jul...
Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) PR Newswire PALO ALTO, Calif. , July 2, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the developm...
Eiger BioPharmaceuticals (EIGR) perks up 7.3% premarket after receiving the 2021 Rare Impact Award for Industry Innovation from the National Organization for Rare Disorders ((NORD)) for the development and approval of Zokinvy (lonafarnib).Zokinvy is the first and only FDA approved t...
Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy® (lonafarnib) PR Newswire PALO ALTO, Calif. , June 29, 2021 /PRNewswire/ -- Eig...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...